Cargando…
Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer
BACKGROUND: In recent years, maintenance chemotherapy is increasingly being recognized as a new treatment strategy to improve the outcome of advanced non-small cell lung cancer (NSCLC). However, the optimal maintenance strategy is still controversial. Gemcitabine is a promising candidate for single-...
Autores principales: | Minami, Seigo, Kijima, Takashi, Shiroyama, Takayuki, Okafuji, Kohei, Hirashima, Tomonori, Uchida, Junji, Imamura, Fumio, Osaki, Tadashi, Nakatani, Takeshi, Ogata, Yoshitaka, Yamamoto, Suguru, Namba, Yoshinobu, Otsuka, Tomoyuki, Tachibana, Isao, Komuta, Kiyoshi, Kawase, Ichiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549766/ https://www.ncbi.nlm.nih.gov/pubmed/23281805 http://dx.doi.org/10.1186/1756-0500-6-3 |
Ejemplares similares
-
Randomized Phase II Study of First‐Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non‐Small Cell Lung Cancer: LOGIK0801
por: Takayama, Koichi, et al.
Publicado: (2020) -
Sequential Therapy with Gemcitabine and Carboplatin Followed by Paclitaxel as First Line Treatment for Advanced Urothelial Cancer
por: Kattan, Joseph G, et al.
Publicado: (2012) -
A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102
por: Yokoi, Takashi, et al.
Publicado: (2019) -
Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
por: Sugimoto, Kazuma, et al.
Publicado: (2022) -
The association of four genetic variants with myelosuppression in gemcitabine‐treated Japanese is not evident in gemcitabine/carboplatin‐treated Swedes
por: Björn, Niclas, et al.
Publicado: (2022)